Abstract-Vascular development is a highly organized sequence of events that requires the correct spatial and temporal expression of specific sets of genes leading to the development of a primary vascular network. The first step in this process is the differentiation of pluripotent stem cells into endothelial cells. This is followed by endothelial proliferation, migration, and eventual formation of endothelial tubes. Maturation of these primitive tubes into fully developed blood vessels requires the recruitment of surrounding pericytes and their differentiation into vascular smooth muscle cells. Many of the events that occur during vasculogenesis are recapitulated during angiogenesis. Transcription factors have been shown to serve as master switches for regulating a number of developmental processes. Using a candidate gene approach, the genomic regulatory regions required to direct vascular-specific gene expression of several receptor tyrosine kinases that are critical for vasculogenesis have been characterized and some of the transcription factors that are involved in the regulation of these genes have recently been identified. Many of these factors are also involved in the regulation of hematopoiesis and may have overlapping functions in determining hematopoietic and endothelial differentiation. Targeted disruption of other transcription factors that were not previously thought to be involved in vascular development have also been recently shown to play a role in blood vessel development. The purpose of this review is to provide an update on the progress that has been made in our understanding of the transcriptional regulation of vascular development over the past few years. (Circ Res. 2001;89:380-388.)
U ntil recently the transcription factors that are necessary for regulating vascular development were largely unknown. This is in sharp contrast to other developmental processes such as hematopoiesis and myogenesis where several cell-or tissue-specific transcription factors have been identified. Vascular development requires the differentiation of endothelial cells from pluripotent stem cells. Progress in identifying the molecular mechanisms underlying vascular development has lagged considerably, in large part because the model systems for studying vascular blood vessel development are more limited. The identification of several vascular-specific genes involved in vasculogenesis and the genomic regulatory regions required for directing their expression over the past decade has facilitated the identification of the transcriptional mechanisms required for vascularspecific gene expression. Targeted disruption of additional transcription factors that have been associated with vascular defects led to the elucidation of a role for these factors in vascular development. Angiogenesis, the development of additional blood vessels from a primary vascular network, may recapitulate many of the molecular events occurring during vascular development. The purpose of this review is to summarize the recent advances made in our understanding of the transcriptional regulation of vascular development and the potential clinical implications this may have for other related processes such as endothelial differentiation and angiogenesis.
Candidate Gene Approach
One common approach to identifying the transcription factors required for a particular process is to examine the transcriptional regulation of specific genes that are known to be critical for the process. This approach has been successful in identifying several of the transcription factors required for Tand B-cell differentiation and has similarly been used to facilitate the identification of the transcription factors required for vascular-specific gene expression. Several receptor tyrosine kinases, including the Flk-1, Flt-1, Tie1, and Tie2 genes, are known to be critical mediators of endothelial differentiation and vascular development. Targeted disruption of all of these genes leads to defects in vascular development and early embryonal lethality. [1] [2] [3] The genomic regulatory regions required for directing vascular-specific gene expression have been identified for several of these genes, which has been verified in vivo by their ability to direct the expression of the ␤-galactosidase (lacZ) gene in transgenic experiments. Interestingly for the Tie1 gene, the promoter alone is sufficient to direct lacZ expression in an endothelial cell-specific fashion. 4 In contrast, for both the Tie2 and Flk-1 genes an intronic enhancer is required to direct complete vascular-specific gene expression. 5, 6 Comparison of the mouse and human DNA sequences within the regulatory regions of these genes has facilitated the identification of conserved binding sites for different classes of transcription factors. Conservation of these sites suggests that the binding of family members of these transcription factors may be required to direct vascular-specific gene expression. Further support for this concept comes from the fact that point mutations in these sites lead to marked reductions in the vascular-specific gene expression of lacZ in transgenic animals. The Tie1 gene promoter contains conserved binding sites for Ets factors and AP-2. 4 Mutations in most of these conserved binding sites leads to marked reductions in the ability of the Tie1 promoter to direct lacZ gene expression in transgenic animals. A similar approach has been used to identify the transcription factor binding sites that are necessary for directing the vascular-specific gene expression of the Flk-1 gene. 6 Conserved binding sites for the Ets factors, SCL/tal-1 factor, and GATA factors were identified. Point mutations in some of these binding sites also lead to marked reductions in the vascular-specific expression directed by the Flk-1 regulatory regions in transgenic studies. Conserved Ets binding sites exist in the Tie2 and Flt-1 genes. 7, 8 The results of these studies strongly support that these transcription factors are involved in the regulation of vascular development.
Although these studies have led to the identification of potential classes of transcription factors that may be required for the direction of vascular-specific gene expression, this has not resulted in the identification of the specific transcription factors within each of these classes. One approach toward identifying the specific transcription factors that are responsible for the regulation of these genes is to perform transactivation studies and compare the ability of the different members of a particular family of factors to transactivate the gene. This approach was used to test the ability of different members of the Ets factor family to transactivate the Flt-1, Tie1, and Tie2 genes. Whereas the Ets factors Ets-1 and Ets-2 most potently transactivated the Flt-1 gene promoter, they were only able to mildly transactivate the Tie1 and Tie2 gene promoters. 4, 8 In contrast, the Ets factors NERF and ELF-1 more potently transactivated the Tie1 and Tie2 genes. 4, 8 The ability of specific Ets factors to transactivate the specific gene targets also correlates with their ability to bind to specific conserved Ets binding sites. This suggests that different subsets of the Ets factors may regulate different vascularspecific genes.
Animal Models of Vascular Development
One of the major difficulties in identifying the specific transcription factors involved in regulating vascular-specific gene expression, particularly as it relates to blood vessel development, is the difficulty in isolating either embryonic or extraembryonic blood vessels during mouse embryogenesis. Because blood vessel development is a highly conserved process over evolution, the use of alternative model systems has permitted easier access to studying blood vessel development. Two animal models that have been particularly useful for these studies include the developing zebrafish and chicken. Both have the advantage of allowing direct visualization of blood vessels. Two genes that have been identified in zebrafish and seem to be critical early regulators for initiating vascular development are cloche and spade tail. 9 Similarly, the stem cell leukemia transcription factor (SCL) was also shown to promote vasculogenesis, hematopoiesis, and endothelial differentiation when expressed ectopically in zebrafish mesoderm. 10 The Ets transcription factor Fli-1 has also been shown to be enriched in the developing blood vessels of zebrafish embryos. 11 As an alternative model of blood vessel development, several investigators have used the developing chicken as an easier model to study blood vessel development because of the easier access to developing blood vessels, particularly in the extraembryonic chorioallantoic membrane. These blood vessels can be microdissected at different stages of development facilitating the determination of whether specific genes are upregulated or enriched in developing blood vessels. This approach was used to identify which of the members of the Ets transcription factor family are upregulated during blood vessel development. A novel role for the Ets factor ELF-1 in vascular development was identified using this approach. 12 In situ hybridization and immunohistochemical experiments confirmed the enriched expression of this factor in extraembryonic and embryonic blood vessels of the developing chicken embryo. 12 The Ets factor Ets-1 has also been shown to be enriched in the developing blood vessels of the chicken and antisense oligonucleotides have been shown to inhibit angiogenesis when delivered to the chicken chorioallantoic membrane. 13 
Conservation of Transcription Factors Involved in Vascular Development
One potential criticism of using nonmammalian models to identify the transcription factors involved in regulating blood vessel development is that the same factors may not necessarily be evolutionarily conserved. Arguing against this is the fact that studies in the chicken and in zebrafish have demonstrated that not only are the factors conserved with regard to protein sequence, but also show a similar enriched expression pattern during vascular development. For example, the helixloop-helix transcription factor SCL is expressed in developing blood vessels and in the vasculature of both the developing mouse and zebrafish. 10, 14 The Ets factor ELF-1, which has previously been identified for its role for T cell-specific gene expression, has also been shown to be a strong transactivator of the Tie1 and Tie2 genes and is highly enriched in developing blood vessels of the developing chicken embryo. The overall homology between the chicken and human ELF-1 protein is 80%. 12 Similarly, the Ets factor Fli-1 has recently been shown to be a critical regulator of blood vessel development not only in zebrafish but also in the mouse. 11, 15 In situ hybridization studies of the developing mouse have also demonstrated that Ets-1 is expressed in developing blood vessels associated with tumor angiogenesis. 16 Targeted disruption of Fli-1 in mice results in a loss of vascular integrity accompanied by bleeding and embryonic lethality at day 11.5. 15 Expression of the Tie2 gene is also downregulated in these mice. The expression of two of the GATA factors, GATA-2 and GATA-3, has recently been examined in human fetal tissues. Both factors are enriched in the developing dorsal aorta at 5 weeks old. 17 
Oettgen Transcriptional Regulation of Vascular DevelopmentTargeted Disruption and Overexpression Studies
An alternative approach that has resulted in the identification of other transcription factors that are required for blood vessel development is through targeted disruption. In many cases this has unexpectedly resulted in determining a novel role for a particular factor in blood vessel development. An example is targeted disruption of the AP-1 transcription factor family member Fra1, which leads to abnormalities in extraembryonic vascularization. 33 The zinc finger transcription factor LKLF is expressed in a variety of vascular and nonvascular cell types. However, targeted disruption of this transcription factor leads to abnormalities in later stages of blood vessel development. 34 Although the early events of both angiogenesis and vasculogenesis were normal in LKLF-deficient mice, they develop abnormalities in the smooth muscle architecture of the tunica media, leading to aneurysmal dilatation of the blood vessels with eventual blood vessel rupture. Diminished numbers of endothelial cells, pericytes, and extracellular matrix deposition are also seen. The transcription factor Tfeb, a bHLH transcription factor, was recently shown to be required for vascularization of the placenta. 35 The homeobox gene Hox D3 is induced in endothelial cells in response to basic fibroblast growth factor (bFGF), and antisense oligonucleotides to Hox D3 block the ability of bFGF to induce the expression of urokinase plasminogen activator. Overexpression of Hox D3 increases integrin ␣ v ␤ 3 expression in endothelial cells. 36 Another homeobox transcription factor that may contribute to both hematopoeisis and endothelial differentiation is hhex. Overexpression of this factor in zebrafish embryos leads to enhanced endothelial and erythroid differentiation. 37 
Overlapping Transcriptional Mechanisms Between the Hematopoietic and Endothelial Lineages
Perhaps one of the most interesting recent findings regarding the transcriptional regulation of vascular development has been the determination that the transcription factor SCL/tal-1, which was originally thought to play a role strictly in hematopoiesis, also seems to be critical for embryonic blood vessel development. Targeted disruption of this gene leads to embryonic lethality by day 9.5, due to an absence of yolk sac erythropoiesis. 52 However, it was unclear whether this gene might also contribute to nonhematopoietic pathways at later stages of development. By performing transgenic experiments in which the GATA-1 promoter is used to restore SCL gene expression in hematopoietic lineages in SCL Ϫ/Ϫ mice, the mice develop striking abnormalities in yolk sac angiogenesis. 14 This suggests that certain transcription factors may be critical for the normal development of both hematopoietic cells and blood vessels, and that there may be a common stem cell precursor for both lineages. The most striking defects were a disorganized array of capillaries and absence of normal vitelline blood vessel formation. Although the larger vitelline blood vessels were not present, a smaller network of interconnecting vessels did exist. The architecture of these vessels revealed normal-appearing endothelial cells as well as the smooth muscle cells or pericytes that constituted the outer lining of the blood vessels. The expression of a number of vascular-specific genes including Tie-1, Tie-2, Flk-1, and Flt-1 also appeared normal. Members of the Ets transcription factor family that were originally described for their role in lymphoid development have now also been shown to regulate vascular-specific genes. The Ets factor NERF was originally identified for its role in regulating the expression of B cell-specific genes such as the tyrosine kinase blk. 53 The NERF gene is expressed as at least three isoforms, NERF1a, NERF1b, and NERF2. Whereas NERF2 is a potent transactivator, the NERF1 isoforms have a truncated transactivation domain and act as natural dominant-negative forms of NERF2. These isoforms are differentially expressed in different cell types. Whereas NERF1a and 1b are expressed in B cells, NERF2 is highly expressed in endothelial cells and is a strong transactivator of the endothelial-specific Tie1 and Tie2 genes. 8 Similarly, the related Ets factor ELF-1, which was originally shown to regulate T cell-specific genes, was also shown to be enriched in developing blood vessels of the chicken. 12 The Ets factor Tel was originally identified for its role as a proto-oncogene in the development of human leukemias. Interestingly, targeted disruption of this factor led not only to defects in hematopoiesis but also to defects in extraembryonic angiogenesis. 54 
Endothelial Differentiation
One of the first steps during vascular development is the differentiation of endothelial cells from pluripotent stem cells. This process initially involves the expression of other endothelial-specific markers such as CD31(PECAM-1). VEcadherin is associated with the differentiation of these cells into mature endothelial cells. The specific transcription factors that mediate these events have not yet been identified. However, the presence of conserved binding sites in the regulatory regions of vascular-specific genes for several of the transcription factors involved in hematopoiesis suggests that members of the same transcription factor families are also involved in the process of endothelial differentiation. Several studies have recently suggested the existence of a common precursor for both endothelial cells and cells of hematopoietic origin. The possible existence of a common precursor was originally suggested because of the close association of hematopoietic cells and endothelial cells in the developing embryos in the so-called blood islands. Hematopoietic and endothelial cells coexpress a number of genes. One of the earliest markers expressed on cells of endothelial and hematopoietic origin is the VEGF receptor flk-1. Further support for the existence of the hemangioblast comes from differentiation of pluripotent embryonic stem cells along endothelial and hematopoietic lineages. 38, 39 When individual blast colonies are allowed to differentiate further, they form adherent cells that express more endothelial-specific markers such as PECAM-1 and Tie2, whereas many of the nonadherent cells presumed to be of hematopoietic origin expressed such genes as ␤-H1 and ␤major, consistent with cells derived from the erythroid lineage. Furthermore, when Flk-1-positive cells were isolated from embryonic stem cells and allowed to differentiate in vitro, they could be sorted into cells of both endothelial and hematopoietic origin by flow cytometry using surface markers specific for endothelial or hematopoietic cells. 40 Some of the specific transcription factors that may be required for endothelial differentiation have recently been identified. The vascular defects seen in mice with targeted disruption of the immediate-early gene Fra1 were partially attributed to a marked reduction in the number of endothelial cells. The defects were mainly seen in the placenta with severely impaired vascular development leading to embryonic lethality between E10.0 and E10.5. 33 The zinc finger transcription factor Vezf1 is expressed solely in vascular endothelial cells and their precursors. 41 Endothelial-specific expression of Vezf1 was also observed in endothelial cells of the developing dorsal aorta, the branchial arch artery, and endocardium and colocalized with Flk-1 expression.
Endothelial Tube Formation
Following their differentiation from pluripotent stem cells, endothelial cells migrate and form primitive tubes. The basic HLH transcription factor HESR1 has recently been shown to be upregulated during endothelial tube formation. 42 Overexpression of this gene in endothelial cells results in downregulation of Flk-1 which may result in inhibiting endothelial cell proliferation by diminishing endothelial responsiveness to VEGF. Antisense oligonucleotides directed against HESR1 were able to block the formation of capillary tubes. The homologue of this factor in zebrafish is called gridlock and is a critical mediator of the development of arteries such as the aorta but not of veins. 43 The homeobox gene HOX B3 has recently been shown to be involved in facilitating capillary morphogenesis. 44 Overexpression of this factor in the chicken chorioallantoic membrane leads to increased capillary vascular density, and antisense oligonucleotides inhibit endothelial tube formation of microvascular endothelial cells cultured on extracellular matrix. Another transcription factor involved in endothelial tube formation is nuclear receptor PPAR-␥. In contrast to HESR1 and HOX B3, ligands that activate this transcription factor block endothelial tube formation and endothelial proliferation. 45 
Smooth Muscle Cell Differentiation
After initial endothelial tube formation, vessel maturation requires the subsequent recruitment of surrounding mesenchymal cells and their differentiation into vascular smooth muscle cells. This process has been shown to involve the interaction of endothelial cells with mesenchymal cells and the release of specific growth factors such as platelet-derived growth factor. 46, 47 A number of transcription factors have also recently been shown to be critical for smooth muscle differentiation (Table) . One family of transcription factors that is crucial for muscle development, in general, is the MADS-box transcription factor family. Two members of this family, SMAD5 and MEF2C, have recently been shown to be important in vascular development and in smooth muscle cell differentiation. 48, 49 Targeted disruption of SMAD5 leads to vascular defects resulting in embryonal lethality at day 10.5 49 Similarly, the targeted disruption of MEF2C leads to abnormalities in smooth muscle cell differentiation and the inability of endothelial cells to form into vascular structures. 48 LKLF is a member of the Krüppel-like family of zinc finger transcription factors. Targeted disruption of this gene leads to vascular defects. Most notably there is a reduction in the number of differentiated smooth muscle cells and pericytes. These defects result in aneurysmal dilatation of the large vessels and eventual rupture with intra-amniotic hemorrhage. 34 A similar phenotype was recently reported for mice lacking the cytoplasmic domain of ephrin B2, suggesting that signaling through ephrin B2 may involve activation of LKLF or similar transcription factors during later stages of blood vessel development. 50 The bHLH transcription factor dHAND has recently been shown to be crucial for yolk sac vascular development. In dHAND null mice, endothelial cell differentiation and recruitment of surrounding mesenchymal cells occurs normally. However, the mesenchymal cells fail to differentiate into vascular smooth muscle cells. 51 One of the genes that was shown to be downregulated in these mice was the VEGF 165 receptor neuropilin, suggesting that dHAND may be a critical mediator of the VEGF signaling pathway.
Transcription Factors Critical for Smooth Muscle Differentiation

Transcriptionally Mediated Hypoxia Responses During Later Stages of Blood Vessel Development
After the development of a primary vascular network, the developing embryo requires the formation of additional blood vessels or angiogenesis. This process is largely driven by hypoxia, which serves as a stimulus for the release of angiogenic growth factors. One of the main classes of transcription factors that promote this process is the basic helix-loop-helix (bHLH)-PAS domain family. A prototype member of this family is the arylhydrocarbon-receptor nuclear translocator (ARNT). 18 ARNT forms a heterodimeric complex with another PAS transcription factor, hypoxiainducible factor 1␣(HIF-1␣). 19 In response to oxygen deprivation, these transcription factors stimulate the expression of such angiogenic factors as vascular endothelial growth factor (VEGF). 20 Targeted disruption of the ARNT gene results in embryonic lethality by day 10.5. 21 Although a primary vascular network forms, the predominant defective angiogenesis occurs in the yolk sac and branchial arches, and overall growth of the embryos is stunted. These defects are similar to those observed in VEGF-or tissue factor-deficient mice. 22, 23 Thus, although the primary vascular network developed, the angiogenic responses to hypoxia are severely impaired. Similar findings are observed in HIF-1␣ knockout mice in which embryonic lethality occurs by day 10.5 as a result of cardiac and vascular malformations. 24 Although neither of these transcription factors is expressed in a vascular-specific way, their role in angiogenesis and vascular development is primarily related to their ability to stimulate the production of angiogenic factors, such as VEGF, in response to hypoxia. A third member of this family of transcription factors, endothelial PAS domain protein 1 (EPAS1), was recently identified. 25 EPAS is predominantly expressed in endothelial cells and can also heterodimerize with ARNT. Targeted disruption of the EPAS gene has been evaluated by two different groups resulting in two different phenotypes. 26, 27 Tian et al 26 detected abnormalities in catecholamine homeostasis in EPAS Ϫ/Ϫ mice and no distinct abnormalities in blood vessel formation, whereas Peng et al 27 identified vascular defects at later stages of embryogenesis during vascular remodeling in their EPAS Ϫ/Ϫ mice. The differences in the phenotype cannot be attributed to differences in targeting construct because both groups disrupted the expression of the bHLH domain, but are more likely attributable to differences in the strain of the mice or subtle differences in the embryonic stem cells used. Although the formation of a primary vascular network or vasculogenesis occurs, later defects in vascular remodeling are observed during large vessel formation associated with hemorrhage and inability of the vessels to fuse properly. This suggests that all three of these PAS family members play a similar role in facilitating later stages of vascular remodeling and angiogenesis in the developing embryo.
Modulation of the function of HIF-1␣ is also achieved by interaction with other proteins. The transcriptional adapter proteins p300 and CREB-binding protein (CBP) form a multiprotein/DNA complex together with HIF-1␣ on the promoters of the VEGF and erythropoietin genes to promote expression of these genes in response to hypoxia. 28 Interestingly, CBP-deficient mice exhibit abnormalities in both vasculogenesis and angiogenesis. 29 In contrast, the von Hippel-Lindau tumor suppressor protein (pVHL) has been shown to promote proteolysis of HIF-1␣ through ubiquitylation under normoxic conditions. Defective VHL function is associated with cancers that exhibit dysregulated angiogenesis and upregulation of hypoxia inducible genes. 30 The signaling mechanisms by which hypoxia activates HIF-1␣ are beginning to be elucidated. The catalytic subunit of phosphatidylinositol (PI) 3-kinase, p110, plays a pivotal role in the induction of HIF-1 activity in response to hypoxia. 31 Both induction of VEGF gene expression and HIF-1␣ activity in response to hypoxia could be blocked by the addition of a PI3-kinase inhibitor. Further support of this concept comes from experiments in which VEGF gene expression and HIF-1 activity is induced by cotransfection of p100. Other studies have recently demonstrated that HIF-1␣ activity may also be modulated by the mitogen-activated protein kinases p42 and p44. 32 
Temporal and Spatial Aspects of Vascular Development
One of most intriguing aspects of any developmental process is how differentiating cells migrate to the proper location in the correct spatial and temporal organization to form specific structures such as organs or tissues. Blood vessel development similarly involves the correct spatial organization of differentiating endothelial and vascular smooth muscle cells. Endothelial differentiation is an early event followed by the formation of primitive tubes. The subsequent recruitment of surrounding mesenchymal cells and their differentiation into vascular smooth muscle cells is a later event leading to the formation of stable blood vessels. Growth factors including platelet-derived growth factor, bFGF, VEGF, angiopoietin-1, and transforming growth factor-␤ (TGF-␤) are key mediators of these events promoting the proliferation and migration of cells. Several of the transcription factors described above are either key regulators of the expression of either the growth factors or their receptors, or mediators of the cellular responses to these growth factors. A summary of the temporal role for these transcription factors is shown in the Figure. One of the earliest transcription factors required for the differentiation of a pluripotent stem cell into a hemangioblast is SCL/tal-1. 64 Knockout studies suggest that two transcription factors that may be required for differentiation or survival of endothelial cells early in development are Fra1 and Vezf1. 33, 41 Another early step in the differentiation of endothelial cells is the expression of VEGF receptors that promote not only the differentiation, but also the proliferation, of endothelial cells. Regulation of the VEGF receptor gene expression is mediated by the Ets transcription factors, GATA factors, and bHLH factor dHAND. 6, 7, 51 The expression of VEGF is largely mediated by the PAS domain family of transcription factors, including HIF-1␣, EPAS, and ARNT in response to hypoxia. The next stage of blood vessel development involves the proliferation and migration of the endothelial cells and their formation into primitive tubes. Endothelial tube formation is regulated at least in part by the transcription factors HESR1 and PPAR-␥. 42, 45 Maturation of primitive endothelial tubes into mature blood vessels requires the recruitment of surrounding mesenchymal cells or pericytes and their differentiation into vascular smooth muscle cells. This process is largely mediated by the angiopoietins and the Tie2 receptor. Tie2 gene expression has been shown to be regulated by the Ets factors NERF, ELF-1, and Fli-1. 8, 12, 15 One of the possible transcriptional regulators of angiopoietin-1 expression is the transcription factor AML1. Targeted disruption of this factor led to abnormalities in angiogenesis that could be rescued by administration of angiopoietin-1. 65 Another transcription factor that also seems to regulate angiopoietin-1 levels is the nuclear receptor COUP-TFII. 66 Targeted disruption of this gene is associated with angiogenic defects and marked reductions in the level of angiopoietin-1. The differentiation of mesenchymal cells into vascular smooth muscle cells is also a highly orchestrated 
Determinants of Vascular Specificity in the Absence of Vascular-Specific Transcription Factors
Although several of the transcription factors that are important for blood vessel formation have been identified, many of them are not particularly endothelial or vascular cell specific. Several of the factors seem to be involved in both hematopoiesis and vasculogenesis. What ultimately determines the formation of blood vessels? Either additional vascular cellspecific proteins are required to promote the regulation of a vascular-specific phenomenon, or it is possible that the right combination of transcription factors in a particular cell type may be equally important. One such recently described additional protein is the zinc finger transcription factor Lmo2, a member of the LIM family of proteins. 55 Lmo2 serves as a bridging molecule between GATA factors and E-box proteins that does not require its direct binding to DNA. 56 62 Mice deficient in Id1 and Id3 exhibit defects in endothelial differentiation and angiogenesis. 63 In summary, these data suggest that these adapter proteins may be just as important in determining tissue-specific expression of certain genes and directing developmental processes. Similar properties are exhibited by the SCL/tal-1 transcription factor that does not require DNA binding for its function. 64 Mutant forms of the SCL gene, lacking the putative DNA binding domain, were able to rescue hematopoietic defects from the phenotype of SCL Ϫ/Ϫ embryos, as well as the hematopoietic and vascular defects of the cloche zebrafish mutants, which are thought to be upstream of SCL.
Another mechanism for providing cell-type specificity, even though the particular factor may be expressed in several cell types, is through differential expression of functionally different isoforms of the transcription factor in different cell types. The Ets transcription factor NERF, for example, which was originally identified as being important in B-cell function by regulating the B cell-specific tyrosine kinase blk, has also subsequently been shown to regulate the Tie2 tyrosine kinase in endothelial cells. 8, 53 The NERF gene has multiple isoforms that are differentially expressed in B cells compared with endothelial cells. 8 
Clinical Implications
The identification of the genomic regulatory regions and the specific transcription factors required for vascular-specific gene expression has several implications regarding the potential treatment of several diseases. First, the identification of vascular-specific fragments allows the possibility of delivering genes and their protein products specifically to blood vessels. The Tie1 promoter has been used not only to direct the expression of the ␤-galactosidase gene in an endothelialspecific fashion but has also been used to express growth hormone. 4 Although these experiments were performed in transgenic animals, they could similarly be used in viral vectors to direct endothelial specific gene expression. Potential therapeutic uses of these vectors include the expression of modulators of inflammation or cell growth in diseases such as the restenosis associated with angioplasty, the vasculopathy related to cardiac transplantation, and the chronic inflammation associated with atherosclerosis. An example of a protein that has been successfully used to treat restenosis is the Fas ligand, which promotes cell death. 67 However, if this gene was expressed in nonvascular cells, it could lead to significant adverse effects. In addition to inflammatory conditions, a vascular-specific promoter might also be used to block vascular growth during tumor growth since most endothelial cells are not actively proliferating. The identification of transcription factors that may serve as master switches of endothelial differentiation or angiogenesis may also allow the use of these factors to be used in a therapeutic manner or serve as a therapeutic target for blocking angiogenesis. The ability of two transcription factors to direct angiogenesis was recently shown in two studies. In the first study, gene delivery of the early growth response transcription factor egr-1 in a wound healing model enhances the degree of angiogenesis and promotes normal healing. 68 Similarly, the administration of a constitutively active form of the transcription factor HIF-1␣ augments the angiogenic response by expression of this transcription factor in vivo in a rabbit model of hind limb ischemia. 69 The fact that several other transcription factors have been shown to be enriched during blood vessel development, or that the targeted disruption of these genes is associated with significant vascular defects, as described above, suggests that these factors may also be used therapeutically to promote angiogenesis. Alternatively, several of these newly identified transcription factors could serve as targets for inhibiting blood vessel development or angiogenesis. Drugs used to augment or interfere with the function of these factors could enhance the development of angiogenesis in such diseases as ischemic heart disease, where the development of new blood vessels may be beneficial. Downregulation or blockade of the function of these factors might also be effective at inhibiting the angiogenesis that promotes such diseases as cancer, rheumatoid arthritis, or diabetic retinopathy.
